Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovation Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Focusing on unmet needs in CNS and oncology, Ovation Pharmaceuticals Inc. will acquire marketed drugs and late-stage candidates that don't represent a big enough payoff to their current manufacturers. The company plans to boost its acquisitions' value by developing new dosages, new formulations and new treatment indications, then add creative sales and marketing muscle to bring its products to the light of day.

You may also be interested in...



The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.

The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.

Chester Valley Pharmaceuticals Inc.

In a year that saw a number of significant private financings in dermatology, Chester Valley Pharmaceuticals Inc. was one of the standouts. The specialty pharma was formed in November 2004 by dermatology industry veterans Robert J. Moccia and Xavier Yon, and by private equity firm GTCR Golder Rauner LLC, which has made a $75 million equity commitment to the new company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel